Trial Profile

Combination of Nanoxel and Herzuma as First-line Chemotherapy in Patients With Metastatic Salivary Duct Carcinoma : Open Label Single Arm Multicenter Phase II Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
Indications Adenocarcinoma; Carcinoma; Salivary gland cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

07 Jun 2022 Primary endpoint has been met (Objective response rate) , according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
30 Dec 2021 Planned End Date changed from 1 Aug 2022 to 1 Aug 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com